Previous 10 | Next 10 |
2023-11-07 18:04:36 ET More on Inozyme Pharma Endpoints Unzipped: Inozyme's INZ-701 Twist In The Plot Seeking Alpha’s Quant Rating on Inozyme Pharma Historical earnings data for Inozyme Pharma Financial information for Inozyme Pharma For furthe...
2023-11-07 09:57:20 ET More on Inozyme Pharma Endpoints Unzipped: Inozyme's INZ-701 Twist In The Plot Seeking Alpha’s Quant Rating on Inozyme Pharma Historical earnings data for Inozyme Pharma Financial information for Inozyme Pharma For furthe...
– Patient recruitment underway in ENERGY-3 Pivotal Trial of INZ-701 in pediatric patients with ENPP1 Deficiency; topline data expected mid-2025 – – Topline data readouts from ongoing Phase 1/2 trials of INZ-701 in adults with ABCC6 Deficiency and ENPP1 Deficiency ex...
2023-10-27 17:09:46 ET Gainers: Coherus BioSciences ( CHRS ) +16% . 2U ( TWOU ) +6% . Sarepta Therapeutics ( SRPT ) +5% . Noodles & Company ( NDLS ) +4% . Intuitive Machines ( LUNR ) +4% . Losers: NKGen Biotech ( NK...
BOSTON, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“Inozyme” or the “Company”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal prolifer...
2023-10-23 17:42:52 ET Gainers: Redfin ( RDFN ) +15% . Agilysys ( AGYS ) +11% . Medpace Holdings ( MEDP ) +5% . HomeStreet ( HMST ) +5% . IDEAYA Biosciences ( IDYA ) +5% . Losers: CareDx ( CDNA ) -8% . A...
2023-10-11 17:30:06 ET Gainers: COMPASS Pathways ( NASDAQ: CMPS ) +5% . Inozyme Pharma ( INZY ) +4% . CommScope Holding ( COMM ) +4% . FTAI Infrastructure ( FIP ) +3% . Aemetis ( AMTX ) +3% . Losers: Lottery ( ...
BOSTON, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“Inozyme” or the “Company”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal prolifer...
BOSTON, Oct. 06, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“Inozyme” or the “Company”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal prolifer...
- Data from ongoing trial suggest clinical benefit for ENPP1 Deficiency, including improvement in key biomarkers, patient reported outcomes (PROs) and functional outcomes - - Improvement in the Global Impression of Change (GIC) observed in all three dose cohorts in ABCC6 Deficiency (PXE) tr...
News, Short Squeeze, Breakout and More Instantly...
2024-07-27 20:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
BOSTON, July 02, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal prolifer...
BOSTON, June 21, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferatio...